ATF1 and leukemia: In leukemia cells of AML patients, it has been reported that H3K9me3 occupancy is reduced in the promoters containing cis-binding sites for ETS and cyclic adenosine monophosphate response elements (CREs) for CREB/CREM/ATF1, and decrease of H3K9me3 is correlated with event-free survival in AML patients with t(8;21), t(15;17), inv(16), or complex karyotype [28].